6-(癸基氨基)-1H-吲哚-4-甲醇 | 123597-55-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 6-(癸基氨基)-1H-吲哚-4-甲醇
• 英文名称: 6-(N-Decylamino)-4-hydroxymethylindole
• 英文别名: [6-(decylamino)-1H-indol-4-yl]methanol
• CAS: 123597-55-7
• 化学式: C₁₉H₃₀N₂O
• 分子量: 302.5
• InChiKey: CHLOVPDKABYEDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  22
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  48
• 氢给体数：
  3
• 氢受体数：
  2

文献信息

• Anti-inflammatory compositions
  申请人：PROCYON PHARMACEUTICALS, INC.

  公开号：EP0455271A2

  公开（公告）日：1991-11-06

  Compounds having anti-inflammatory and other activities. The compounds are derived from diterpenes, indol alkaloids, polyacetates, diaminobenzyl alcohols, diacylglycerol and bryostatins.

  具有消炎和其他活性的化合物。这些化合物来自二萜、吲哚生物碱、多乙酸酯、二氨基苄醇、二酰甘油和白藜芦醇。
• Use of a modulator of protein phosphorylation in the treatment of amyloidosis associated with Alzheimer's disease
  申请人：THE ROCKEFELLER UNIVERSITY

  公开号：EP0457295A2

  公开（公告）日：1991-11-21

  Disclosed is the use of at lease one kinase modulator or phosphatase modulator being capable of increasing or decreasing the rate of proteolytic processing of proteins found in intracellular neurofibrillary tangles and extracellular amyloid plaques for the preparation of a pharmaceutical composition for the treatment of amyloidosis associated with Alzheimer's disease, wherein said pharmaceutical composition contains said modulator in an amount effectively regulating phosphorylation of said proteins.

  公开了至少一种激酶调节剂或磷酸酶调节剂的用途，它们能够提高或降低细胞内神经纤维缠结和细胞外淀粉样斑块中蛋白质的蛋白水解处理速度，用于制备治疗与阿尔茨海默病相关的淀粉样变性的药物组合物，其中所述药物组合物含有所述调节剂，其用量可有效调节所述蛋白质的磷酸化。
• IMMUNOMODULATOR
  申请人：National University Corporation Nara Institute of Science and Technology

  公开号：EP3501519A1

  公开（公告）日：2019-06-26

  The present invention provides a pharmaceutical composition to be used for the treatment or prophylaxis of allergic diseases. More specifically, the present invention provides a pharmaceutical composition to be used for the treatment or prophylaxis of allergic diseases, which contains a substance that induces selective IgA class switching in B cells. As a substance that induces selective IgA class switching in B cells, a PKC activator can be used. In addition, a composition containing a substance that induces selective IgA class switching in B cells can also be useful as a mucosal adjuvant.

  本发明提供了一种用于治疗或预防过敏性疾病的药物组合物。更具体地说，本发明提供了一种用于治疗或预防过敏性疾病的药物组合物，其中含有一种能诱导 B 细胞选择性 IgA 类转换的物质。作为诱导 B 细胞选择性 IgA 类转换的物质，可以使用 PKC 激活剂。此外，含有诱导 B 细胞选择性 IgA 类转换物质的组合物还可用作粘膜佐剂。
• Methods for inducing synaptogenesis with synaptic growth factor activating compounds
  申请人：NEUROTROPE BIOSCIENCE, INC.

  公开号：US11045447B2

  公开（公告）日：2021-06-29

  A method for treating Alzheimer's disease (AD) by administering to an AD patient a PKC activator, such as a bryostatin-1, without administering a NMDA receptor antagonist, such as memantine.

  一种治疗阿尔茨海默病（AD）的方法，通过向 AD 患者施用 PKC 激活剂（如白僵菌素-1），而不施用 NMDA 受体拮抗剂（如美金刚）。
• Immunomodulator
  申请人：NATIONAL UNIVERSITY CORPORATION NARA INSTITUTE OF SCIENCE AND TECHNOLOGY

  公开号：US11123324B2

  公开（公告）日：2021-09-21

  The present invention provides a pharmaceutical composition to be used for the treatment or prophylaxis of allergic diseases. More specifically, the present invention provides a pharmaceutical composition to be used for the treatment or prophylaxis of allergic diseases, which contains a substance that induces selective IgA class switching in B cells. As a substance that induces selective IgA class switching in B cells, a PKC activator can be used. In addition, a composition containing a substance that induces selective IgA class switching in B cells can also be useful as a mucosal adjuvant.

  本发明提供了一种用于治疗或预防过敏性疾病的药物组合物。更具体地说，本发明提供了一种用于治疗或预防过敏性疾病的药物组合物，其中含有一种能诱导 B 细胞选择性 IgA 类转换的物质。作为诱导 B 细胞选择性 IgA 类转换的物质，可以使用 PKC 激活剂。此外，含有诱导 B 细胞选择性 IgA 类转换物质的组合物还可用作粘膜佐剂。